#United States #REGENXBIO #Diabetic Retinopathy #Rockville, MD #Surabgene Lomparvovec

REGENXBIO's Significant Step in Diabetic Retinopathy Treatment

REGENXBIO Inc. has reached a substantial milestone by initiating the Phase IIb/III NAAVIGATE clinical trial, evaluating its investigational gene therapy, surabgene lomparvovec (also known as sura-vec or ABBV-RGX-314), specifically targeting diabetic retinopathy (DR). On June 29, 2026, the company celebrated dosing its first participant, marking a pivotal advancement in its collaboration with AbbVie.

A New Hope for Diabetic Retinopathy Patients

The urgency of combating diabetic retinopathy is underscored by its status as a leading cause of vision loss among adults worldwide. Dr. Steve Pakola, REGENXBIO's Chief Medical Officer, expressed enthusiasm over the start of this trial, emphasizing the potential of sura-vec to offer a long-lasting treatment with a single administration. Current treatment regimens often involve repeated procedures, which can be burdensome and may lead to undertreatment, worsening patients' conditions.

Understanding the Clinical Trial

The NAAVIGATE trial aims to determine the safety and efficacy of sura-vec among subjects diagnosed with non-proliferative diabetic retinopathy (NPDR) who do not have center-involved diabetic macular edema (CI-DME). In this multicenter, randomized trial, participants will receive a dose of 1.0x10^12 genome copies per eye, similar to what was explored in the previous ALTITUDE trial. The primary objective of this study is to achieve a notable improvement (greater than two steps) on the diabetic retinopathy severity scale (DRSS) over a year-long period. This trial is expected to enroll approximately 135 participants scattered throughout the United States.

The Role of Innovative Gene Therapy

Sura-vec is designed to address the underlying biological mechanisms in diabetic retinopathy by targeting vascular endothelial growth factor (VEGF), a key player in pathological conditions that lead to vision loss. Dr. Arshad Khanani, a noted clinical researcher, highlighted the transformative potential of a one-time, in-office treatment, proposing that it could revolutionize how DR is managed globally.

The optimism surrounding sura-vec is bolstered by data from previous studies, which showcased its durable efficacy with no significant adverse effects, like intraocular inflammation. REGENXBIO's commitment to this innovative gene therapy approach could pave the way for a new paradigm in managing progressive retinal diseases.

Ongoing Research and Future Developments

In addition to the NAAVIGATE trial, REGENXBIO plans to present data from the long-term follow-up of the ALTITUDE study and future pivotal trials in July 2026 at the American Society of Retina Specialists (ASRS) annual meeting. These findings could shine a light on the therapeutic effects of sura-vec over prolonged periods and its safety profile.

REGENXBIO, founded in 2009, aims to leverage the curative potential of gene therapy to enhance patients' lives. Their innovative approach not only targets retinal diseases but also encompasses various rare genetic disorders, indicating their broad commitment to the advancement of gene therapies.

Conclusion

With the launch of the NAAVIGATE trial, REGENXBIO is taking a bold step towards potentially revolutionizing the treatment landscape for diabetic retinopathy. By providing a single-location gene therapy with lasting effects, the company seeks to improve patient outcomes and radically shift how chronic retinal diseases are treated. As this critical trial progresses, the eyes of the medical community and patients alike will be fixed on the results, hopeful for a future where vision loss from diabetic retinopathy could be significantly mitigated.